Related Experiment Video
Updated: Jan 11, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
A Comprehensive Review on Human Metapneumovirus.
Uma Agarwal1, Swati Paliwal1, Rajiv Kumar Tonk1
1Department of Pharmaceutical Chemistry, Delhi Pharmaceutical Sciences & Research University, Delhi, 110017, India.
Human metapneumovirus (HMPV) causes respiratory illness but is less severe than HRSV and doesn't show seasonal trends. Co-infections and kidney injury risks need further study.
Area of Science:
- Virology
- Public Health
- Infectious Diseases
Background:
- Human metapneumovirus (HMPV) is a respiratory virus with cold-like symptoms, transmitted via droplets and surfaces.
- It poses a significant threat to vulnerable populations, especially young children, and contributes to infant mortality.
- HMPV was first identified in 2001, highlighting ongoing research into its impact.
Purpose of the Study:
- To consolidate vital information on human metapneumovirus (HMPV) and its effects on respiratory illnesses.
- To advance the understanding of HMPV-related diseases and inform public health responses.
- To identify knowledge gaps and guide future research and interventions for HMPV.
Main Methods:
- A comprehensive literature search was conducted using major databases up to May 2025.
- Studies were selected based on extensive prior research concerning human metapneumovirus globally.
- The review synthesized existing data on HMPV epidemiology, clinical features, and outcomes.
Main Results:
- HMPV exhibits gradual mutations, leading to new strains with moderate variations in clinical presentation.
- Unlike other respiratory viruses, HMPV shows no significant seasonal incidence patterns.
- HMPV infections are generally less severe than HRSV, but co-infections in children increase severity and risk of acute kidney injury (AKI).
Conclusions:
- HMPV's evolutionary trajectory limits pandemic potential, but co-infections and AKI risk necessitate monitoring and research.
- Pre-existing immunity may mitigate HMPV effects, suggesting potential for vaccines or immune-boosting strategies.
- Further research and routine HMPV testing are crucial for developing effective treatments and prevention strategies, especially for at-risk groups.
Related Concept Videos
Pneumonia II: Pathophysiology
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Viral Mutations
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

